700805-72-7

Upstream product

• 79463-77-7 N-cyanodiphenylcarbonimidate 
• 63-74-1 sulfanilamide 

Downstream Products

• 863030-73-3 N₃-[(4-aminosulfonyl)phenyl]-1-(acetyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-68-6 N₃-[(4-aminosulfonyl)phenyl]-1-(4'-nitrobenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 443797-96-4 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide 
• 863030-71-1 N₃-[(4-aminosulfonyl)phenyl]-1-(4'-methoxybenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-75-5 N₃-[(4-aminosulfonyl)phenyl]-1-(4'-chlorobenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 886584-09-4 3-(S)-{6-[5-amino-3-(4-sulfamoylphenylamino)-[1,2,4]triazol-1-yl]-5-methoxypyrimidin-4-ylamino}piperidine-1-carboxylic acid tert-butyl ester 
• 844890-58-0 4-[5-amino-1-(2-chloro-pyridin-4-yl)-1H-[1,2,4]triazol-3-ylamino]-benzenesulfonamide 
• 863030-62-0 N₃-[(4-aminosulfonyl)phenyl]-1-(2'-methoxybenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-64-2 N₃-[(4-aminosulfonyl)phenyl]-1-(3'-nitrobenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-70-0 N₃-[(4-aminosulfonyl)phenyl]-1-(4'-phenylbenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-69-7 N₃-[(4-aminosulfonyl)phenyl]-1-(4'-hydroxybenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-61-9 N₃-[(4-aminosulfonyl)phenyl]-1-(2'-chlorobenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-63-1 N₃-[(4-aminosulfonyl)phenyl]-1-(2'-bromobenzoyl)-1H-1,2,4-triazole-3,5-diamine 
• 863030-65-3 N₃-[(4-aminosulfonyl)phenyl]-1-[3'-(trifluoromethyl)benzoyl]-1H-1,2,4-triazole-3,5-diamine 

Relevant academic research and scientific papers

Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Janus kinases (JAKs) are non-receptor tyrosine kinases that are essential components of the JAK-STAT signaling pathway. Associated aberrant signaling is responsible for many forms of cancer and disorders of the immune system. The present focus is on the d

Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3

Tyrosine kinase 2 (TYK2) is required for signaling of interleukin-23 (IL-23), which plays a key role in rheumatoid arthritis. Presented is the design and synthesis of 1,2,4-triazoles, and the evaluation of their inhibitory activity against the Janus associated kinases TYK2 and JAKs 1-3.

DIAMINOTRIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES

The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIAZOLE COMPOUNDS

The present invention is directed to a novel process for the preparation of substituted triazole compounds, useful in the treating or ameliorating a selective kinase or dual-kinase mediated disorder. The process of the present invention preferentially pro

1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities

A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells. Representative compound 3b demonstrated in vivo efficacy in a human melanoma A375 xenograft model in nude mice.